<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899483</url>
  </required_header>
  <id_info>
    <org_study_id>RRK3545</org_study_id>
    <nct_id>NCT00899483</nct_id>
  </id_info>
  <brief_title>Can Enhanced Glycemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?</brief_title>
  <acronym>GUIDE</acronym>
  <official_title>Can Enhanced Glycaemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Birmingham</source>
  <brief_summary>
    <textblock>
      The investigators have previously demonstrated that the administration of insulin in the form
      of an infusion with additional sugar and potassium may improve cardiovascular performance and
      reduce biochemical evidence of heart muscle injury in non-diabetic patients undergoing
      coronary artery surgery. The investigators now seek to demonstrate that similar benefits can
      be achieved in diabetic patients by administering insulin to maintain as near absolutely
      normal sugar levels as possible.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in the mean left ventricular end-systolic volume index (LVESVI) after CABG and the amount of new permanent injury detected in the late CMRI study</measure>
    <time_frame>3 months post CABG</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycaemic control will be assessed 2 hours pre-operatively and 72 hours post-operatively. Measurement timings will be standardized allowing comparison of glycaemic control during different time-periods.</measure>
    <time_frame>72 hours post CABG</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal departmental practice using dextrose insulin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose potassium insulin solution</intervention_name>
    <description>Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II diabetes mellitus patients (as defined by WHO)

          -  Diet, oral hypoglycaemic or insulin therapy

          -  Undergoing elective and urgent coronary artery bypass surgery

        Exclusion Criteria:

          -  Non-diabetics

          -  Emergency and redo CABG

          -  &lt; 18 years

          -  Pregnancy

          -  Dialysis-dependence

          -  History of CVA/TIA &lt; 6 months

          -  Heart valve disease requiring surgery

          -  STEMI &lt; 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert S Bonser</last_name>
    <phone>0121 4721311</phone>
    <phone_ext>2559</phone_ext>
    <email>mailto:Robert.Bonser@uhb.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashvini Menon</last_name>
    <phone>07973674826</phone>
    <email>ashvini.menon@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert S Bonser</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashvini Menon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael P Frenneaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 11, 2009</last_update_submitted>
  <last_update_submitted_qc>May 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Robert S Bonser</name_title>
    <organization>University Hospital Birmingham</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

